Cagrilintide
Also referred to as: AM833, long-acting amylin analog
A long-acting copy of a natural fullness hormone (amylin), studied in trials for weight and fat loss — often alongside semaglutide.
In plain terms: Cagrilintide is a lab-made, long-lasting copy of amylin, a natural hormone that helps you feel full after eating. It is studied for weight and fat loss, often in combination with semaglutide (the pair is nicknamed "CagriSema"). It is experimental — still being tested, not approved.
- Name
- Cagrilintide
- Aliases
- AM833, long-acting amylin analog
- Classification
- Amylin analog (peptide)
- Areas studied
- Appetite, Weight & fat loss, Amylin signal
What it is
Cagrilintide is a lab-made version of amylin, a hormone released alongside insulin that helps signal fullness. It is engineered to last about a week in the body, so it can be used once weekly in research.
It is studied both on its own and combined with semaglutide. As an experimental compound, it is not an approved medicine.
Mechanism
Amylin works in the brain to tell you that you have eaten enough. Cagrilintide acts on the same amylin/calcitonin signaling system to extend that fullness signal.
The interest in pairing it with semaglutide is that the two hormones reduce appetite through different routes, which researchers study for a combined effect on weight and fat loss.
Areas studied & investigated
The categories below summarize where Cagrilintide appears in the research literature. They describe what the compound is studied for and investigated in — not approved uses, and not guidance for any kind of use.
Fullness signal
Studied for how it extends the natural amylin "I am full" signal in the brain.
Weight & fat loss
Studied in clinical trials in connection with body weight and fat loss.
Combination with semaglutide
A major research focus is pairing it with semaglutide for an additive effect.
Amylin biology
A leading research example of a long-acting amylin analog.
Research history
Cagrilintide came out of research into long-acting amylin hormones. It entered registered clinical trials in the early 2020s, with phase 2 results published in The Lancet and combination work in major journals.
State of the literature
Cagrilintide has been studied in registered human clinical trials, with results in major journals. It is still experimental and not approved. Research, especially in combination with semaglutide, is ongoing.
What to keep in mind
Cagrilintide is experimental — "promising in trials" is not the same as "approved and proven safe for general use." Much of the buzz is about the semaglutide combination, which is still under study. Treat the published trial results as the real evidence and be wary of an experimental compound being presented as a finished product.
Research tools
Evaluating a Cagrilintide batch for laboratory research? These free, research-use-only calculators help you work the numbers and read the paperwork: the reconstitution calculator solves vial concentration and draw volume, and the COA reader walks a certificate line by line. For how much and how often Cagrilintide is commonly used, see the dosing guides.
Batch-tested with published COAs
See what a published COA looks like
Midwest Compounds does not currently list Cagrilintide. Every compound it does sell is tested by an independent lab, with a batch-linked certificate of analysis you can check before you buy.
Citations
The summary above is drawn from published, peer-reviewed sources. Links open the abstract on PubMed, or the free full text on PubMed Central (PMC) where marked.
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. The Lancet, 2021. Abstract
- Kruse T, et al. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Current Obesity Reports, 2023. Abstract